Genetic Therapies Bootcamp: Foundations, Frontiers, and Clinical Engagement OnDemand-03-10 15-05 318-323 Berry-kravis Session 3 Clinical Trials Training

Video Transcription

Video Summary

The speaker discusses challenges and innovations in clinical trials for rare genetic diseases, emphasizing the lengthy and costly drug development process that averages 13 years and multiple trial phases. Traditional clinical trial designs often fail for rare diseases due to small, heterogeneous patient populations and complex, variable phenotypes. Key difficulties include identifying appropriate outcome measures, as genetic diseases affect multiple domains differently in each patient, making single primary endpoints inadequate.<br /><br />The speaker highlights the need for novel trial designs and multi-domain outcome strategies, such as disease-specific rating scales, clinician global impressions, composite measures, and multi-domain responder indices. Each approach has pros and cons, with issues ranging from time-consuming validation to FDA acceptance challenges. Natural history studies and personalized trials, where patients serve as their own controls, offer promising ways to handle heterogeneity and low patient numbers.<br /><br />Examples include successes in Niemann-Pick type C, Angelman syndrome, and Rett syndrome, where natural history data and innovative endpoints improved trial feasibility and regulatory acceptance. Biomarkers like EEG patterns and biochemical markers also show potential as surrogate outcomes. The talk concludes that genetic diseases require mechanistic treatments coupled with new, adaptable trial designs and outcome measures, urging collaborative efforts to advance therapies for rare disorders.

Keywords

rare genetic diseases

clinical trial challenges

drug development process

novel trial designs

multi-domain outcome measures

natural history studies

biomarkers in trials